Tang Capital Acquisition (Stock-Only)

General Information
Business:	(Incorporated in the Cayman Islands) We are a newly organized blank check company established by Tang Capital – as our name indicates. We intend to focus on development-stage biopharmaceutical companies. Note: We are offering only stock in our SPAC IPO – a departure from the usual structure of a unit offering with each unit consisting of a share of stock plus a warrant or a right – or a fraction of a warrant or a right – or both. Note: Our stock is being offered at $25.00 per share – a departure from the usual SPAC IPO price of $10.00 per unit or $10.00 per share. Kevin Tang is our CEO and chairman of the board. He is the founder and president of Tang Capital Management, a life sciences investment firm. He is also the CEO of Aurinia Pharmaceuticals. Michael Hearne is our CFO. He also serves as the CFO of Tang Capital. Ryan Cole is our CFF. He is the COO of Aurinia Pharmaceuticals. (Note: Tang Capital Acquisition filed its S-1 on Oct. 6, 2026, and disclosed the terms for its SPAC IPO – 3.0 million shares at a price of $25.00 per share – to raise $75 million.)
Industry:	BLANK CHECKS
Employees:	0
Founded:	2026
Contact Information
Address	4747 Executive Drive, Suite 210 San Diego, California 92121
Phone Number	(858) 200-3830
Web Address
View Prospectus:	Tang Capital Acquisition (Stock-Only)
Financial Information
Market Cap	$75.0mil
Revenues	$0.0 mil (last 12 months)
Net Income	$0.0 mil (last 12 months)
IPO Profile
Symbol	TCAA
Exchange	NASDAQ
Shares (millions):	3.0
Price range	$25.00 - $25.00
Est. $ Volume	$75.0 mil
Manager / Joint Managers	LifeSci Capital/Raymond James
CO-Managers
Expected To Trade:
Status:	TBA
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

Tang Capital Acquisition (Stock-Only)

(Incorporated in the Cayman Islands)

We are a newly organized blank check company established by Tang Capital – as our name indicates. We intend to focus on development-stage biopharmaceutical companies.

Note: We are offering only stock in our SPAC IPO – a departure from the usual structure of a unit offering with each unit consisting of a share of stock plus a warrant or a right – or a fraction of a warrant or a right – or both.

Note: Our stock is being offered at $25.00 per share – a departure from the usual SPAC IPO price of $10.00 per unit or $10.00 per share.

Kevin Tang is our CEO and chairman of the board. He is the founder and president of Tang Capital Management, a life sciences investment firm. He is also the CEO of Aurinia Pharmaceuticals.

Michael Hearne is our CFO. He also serves as the CFO of Tang Capital.

Ryan Cole is our CFF. He is the COO of Aurinia Pharmaceuticals.

(Note: Tang Capital Acquisition filed its S-1 on Oct. 6, 2026, and disclosed the terms for its SPAC IPO – 3.0 million shares at a price of $25.00 per share – to raise $75 million.)